Skip to content

Study · Animal study (in vivo) · mouse · 2012

8 results

Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.

Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginski M, Paterson BM, Murray JA, Verdu EF, Alkan SS, Pandey NB

Peptides27 Feb 2012Cited by 95 (Europe PMC)

PMID22401908 (opens in a new tab)DOI10.1016/j.peptides.2012.02.015 (opens in a new tab)PepBankPUB-22401908
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In gliadin-sensitized transgenic mice, larazotide inhibited gliadin-induced intestinal macrophage accumulation.

    In plain wordsIn mice, larazotide reduced intestinal macrophage accumulation compared with gliadin challenge without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseIntestinal macrophage accumulation
    Study

    mousen: not reported in source

    Gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice
    Comparator
    Challenge without larazotide
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In gliadin-sensitized transgenic mice, larazotide preserved normal tight junction structure.

    In plain wordsIn mice, larazotide preserved normal tight junction structure compared with gliadin challenge without larazotide.

    Peptide
    Larazotide
    Outcome
    Not applicableTight junction structure
    Study

    mousen: not reported in source

    Gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  3. 03LabIn vitro (cells)Mechanism

    In Caco-2 and IEC6 cells, larazotide inhibited ZO-1 redistribution and rearrangement caused by AT-1002 and gliadin fragments.

    In plain wordsIn cells, larazotide inhibited challenge-induced changes in ZO-1 distribution compared with the challenge without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseZO-1 redistribution and rearrangement
    Study

    n: not reported in source

    Caco-2 and IEC6 cells
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  4. 04LabIn vitro (cells)Mechanism

    In Caco-2 and IEC6 cells, larazotide inhibited actin redistribution and rearrangement caused by AT-1002 and gliadin fragments.

    In plain wordsIn cells, larazotide inhibited challenge-induced changes in actin distribution compared with the challenge without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseActin redistribution and rearrangement
    Study

    n: not reported in source

    Caco-2 and IEC6 cells
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  5. 05LabIn vitro (cells)Mechanism

    In Caco-2 cells, larazotide inhibited the AT-1002-induced reduction in transepithelial electrical resistance.

    In plain wordsIn cells, larazotide inhibited the AT-1002-induced fall in electrical resistance compared with AT-1002 without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseTEER reduction
    Study

    n: not reported in source

    Caco-2 cells
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  6. 06LabIn vitro (cells)Mechanism

    In Caco-2 cells, larazotide inhibited AT-1002-induced tight junction opening.

    In plain wordsIn cells, larazotide inhibited tight junction opening compared with AT-1002 without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseTight junction opening
    Study

    n: not reported in source

    Caco-2 cells
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  7. 07LabIn vitro (cells)Mechanism

    In Caco-2 monolayers, larazotide inhibited translocation of a gliadin 13-mer peptide.

    In plain wordsIn cells, larazotide reduced gliadin peptide passage compared with the challenge without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseGliadin peptide translocation
    Study

    n: not reported in source

    Caco-2 monolayers
    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, larazotide acetate inhibited the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.
  8. 08LabIn vitro (cells)Mechanism

    In epithelial cells, apical larazotide inhibited the permeability increase induced by basolateral cytokines.

    In plain wordsIn cells, larazotide inhibited the permeability increase caused by cytokines compared with cytokines without larazotide.

    Peptide
    Larazotide
    Outcome
    DecreaseCytokine-induced tight junction permeability
    Study

    n: not reported in source

    Comparator
    Challenge without larazotide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · apical applicationAs given in this study.

    Source sentences

    Summary
    Further, apically applied larazotide acetate inhibited the increase in TJ permeability elicited by basolaterally applied cytokines.
    1 context sentence
    Summary · context
    Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.